Literature DB >> 6137804

Glycogen storage disease type 1b: microsomal glucose-6-phosphatase system in two patients with different clinical findings.

K Narisawa, H Otomo, Y Igarashi, N Arai, M Otake, K Tada, T Kuzuya.   

Abstract

The basic defect in glycogen storage disease (GSD) type 1b was investigated in two patients: one, (Y.S.), a severely affected infant and the other, (Y.M.), an adult with mild clinical symptoms. The enzymatic studies on liver needle biopsy specimens from the two patients indicated that glucose-6-phosphate (G-6-P) phosphohydrolase activity of the "intact microsomes" was partially deficient (20% of that in controls) in Y.M. and undetectable in Y.S. Activities of G-6-P phosphohydrolase in the disrupted microsomes of Y.S. and Y.M. are higher than those in the disrupted microsomes of controls (12.60 mumole/min/g liver in Y.S., 9.18 in Y.M. and 6.26 +/- 1.22, mean +/- S.D. in controls). Our study also shows that PPi phosphohydrolase activities of the "intact microsomes" from both patients (6.07 mumol/min/g liver in Y.S. and 5.36 in Y.M.) were greater than those of the controls (3.23 +/- 0.77 mumole/min/g wet weight liver). These results indicate that the G-6-P translocase was the locus of the defect in both patients with GSD type 1b. Clinical symptoms and enzymatic studies suggest that the clinical severity of this disorder depends on the level of residual activities of G-6-P translocase. Kinetic studies showed an abnormally high Km of the residual G-6-P translocase in Y.M., suggesting a structural gene mutation. The systematic assay method for glucose-6-phosphatase system, which requires only 15 mg of liver tissues, is also described.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137804     DOI: 10.1203/00006450-198307000-00006

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  Impaired glucose transport in polymorphonuclear leukocytes in glycogen storage disease Ib.

Authors:  N Bashan; R Potashnik; Y Hagay; S W Moses
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

2.  Neutropenia and neutrophil dysfunction in glycogen storage disease type 1c.

Authors:  G Visser; J Herwig; J P Rake; K E Niezen-Koning; A J Verhoeven; G P Smit
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

3.  Neutrophil metabolic dysfunction in genetically heterogeneous patients with glycogen storage disease type 1b.

Authors:  K Narisawa; S Ishizawa; H Okumura; K Tada; T Kuzuya
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

4.  Intestinal function in glycogen storage disease type I.

Authors:  G Visser; J P Rake; F T M Kokke; P G J Nikkels; P J J Sauer; G P A Smit
Journal:  J Inherit Metab Dis       Date:  2002-08       Impact factor: 4.982

5.  Impaired carbohydrate metabolism of polymorphonuclear leukocytes in glycogen storage disease Ib.

Authors:  N Bashan; Y Hagai; R Potashnik; S W Moses
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

6.  Postnatal regression of glucose transport in a patient with glycogen storage disease type 1b.

Authors:  J Levy; M T Abu-Ras; T Berenstein; R Potashnik; I Meisner; S W Moses; N Bashan
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 7.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

8.  Characterization of the mutations in the glucose-6-phosphatase gene in Israeli patients with glycogen storage disease type 1a: R83C in six Jews and a novel V166G mutation in a Muslim Arab.

Authors:  R Parvari; S Moses; E Hershkovitz; R Carmi; N Bashan
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

9.  Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study.

Authors:  J P Rake; G Visser; D Huismans; S Huitema; E van der Veer; D A Piers; G P A Smit
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.